Nucleai Revolutionizes Clinical Trials with $14M Funding Boost
April 5, 2024, 9:34 pm
Location: United States, Illinois, Chicago
Employees: 51-200
Founded date: 2018
Total raised: $47M
Nucleai, a pioneer in spatial AI biomarkers, has secured a hefty $14M in funding led by M Ventures, the corporate venture arm of Merck KGaA. This investment brings Nucleai's total funding to a solid $60M, fueling their mission to transform personalized medicine through AI-powered patient selection for clinical trials.
Nucleai's cutting-edge technology deciphers the intricate conversations between cells within tissue samples, using AI and machine learning to translate this cellular dialogue into a dynamic "action plan" for pathologists. This empowers them to navigate complex diseases like cancer with unmatched precision, ultimately leading to better patient outcomes.
The new funding will propel Nucleai's AI algorithms to the forefront of clinical trial design, personalizing therapy based on each patient's unique cellular landscape. This ensures optimal selection of participants, particularly for advanced treatments like antibody-drug conjugates (ADCs) and bi-specifics. Nucleai's personalized approach not only increases the success rate of clinical trials but also accelerates the process of bringing new therapies to patients in need.
Nucleai's AI platform goes beyond traditional pathology's static analysis, analyzing pathology images and spatial data at a cellular and tissue level to extract critical details about the tumor microenvironment, cellular morphology, and interactions between cell types. This deep understanding revolutionizes drug development, biomarker discovery, and therapeutic targeting, paving the way for more effective and personalized treatment options.
CEO and Co-Founder of Nucleai, Avi Veidman, expressed, "M Ventures' investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics. Our vision is that every next-generation therapeutic is accompanied with an AI-enabled companion diagnostic, ensuring that each patient's treatment pathway is informed and efficacious. This funding positions us to scale spatial AI, not just to intercept but anticipate the complex behavior of diseases."
Nucleai's cutting-edge technology deciphers the intricate conversations between cells within tissue samples, using AI and machine learning to translate this cellular dialogue into a dynamic "action plan" for pathologists. This empowers them to navigate complex diseases like cancer with unmatched precision, ultimately leading to better patient outcomes.
The new funding will propel Nucleai's AI algorithms to the forefront of clinical trial design, personalizing therapy based on each patient's unique cellular landscape. This ensures optimal selection of participants, particularly for advanced treatments like antibody-drug conjugates (ADCs) and bi-specifics. Nucleai's personalized approach not only increases the success rate of clinical trials but also accelerates the process of bringing new therapies to patients in need.
Nucleai's AI platform goes beyond traditional pathology's static analysis, analyzing pathology images and spatial data at a cellular and tissue level to extract critical details about the tumor microenvironment, cellular morphology, and interactions between cell types. This deep understanding revolutionizes drug development, biomarker discovery, and therapeutic targeting, paving the way for more effective and personalized treatment options.
CEO and Co-Founder of Nucleai, Avi Veidman, expressed, "M Ventures' investment boosts our ability to scale and deploy our spatial AI technology for patient enrollment in clinical trials and supports our work in the rapidly emerging areas of immunotherapies, antibody-drug conjugates, and bi-specifics. Our vision is that every next-generation therapeutic is accompanied with an AI-enabled companion diagnostic, ensuring that each patient's treatment pathway is informed and efficacious. This funding positions us to scale spatial AI, not just to intercept but anticipate the complex behavior of diseases."